Doseology Shares-for-Debt Settlement, Director Resignation
Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The impact on broader markets is negligible given the tiny dollar value of the settlement and the micro-cap status of Doseology Sciences Inc. Any effect is confined to the company's own shares on the Canadian Securities Exchange, where the modest dilution from 75,268 new shares at $0.18 may weigh marginally on the stock.
Doseology Sciences Inc., a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announced on September 23, 2026 that it proposes to issue an aggregate of 75,268 common shares at a deemed price of $0.18 per share to settle $13,548.39 in accrued share-based consulting compensation owed to a former consultant. The deemed issue price was determined by reference to the closing price of the company's common shares on the Canadian Securities Exchange on the trading day immediately preceding the announcement, in accordance with CSE policies. Subject to satisfaction of applicable corporate, securities law and CSE requirements, Doseology anticipates completing the settlement on or about September 30, 2026. The settlement shares will be subject to applicable resale restrictions under Canadian securities laws and any hold period imposed under CSE policies. Separately, the company announced that Daniel Vice has resigned as a director of the company, effective September 17, 2026. The company, led by CEO and Director Chris Jackson, wished Mr. Vice well in his future endeavours. The transaction is a small, routine administrative share issuance by a micro-cap issuer and carries negligible broader market significance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard